Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2b randomized double-blind placebo-controlled study of tulisokibart in radiographic axial spondyloarthritis (ankylosing spondylitis)
CTR20254031Phase 2Active
- Sponsor
- Merck & Co.
- Start
- Feb 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of tulisokibart in ankylosing spondylitis (AS), sponsored by Merck & Co.. Started Feb 2026; status: active.
02
Drugs
tulisokibart
03
Conditions
ankylosing spondylitis (AS)
Beyond the preview
Go deeper on CTR20254031.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20254031.